Core Viewpoint - Water Lily Consultants Inc., one of the largest shareholders of the company, has voluntarily committed to extend the lock-up period for its shares until July 2, 2026, indicating confidence in the company's future prospects and recognition of significant progress in the development and commercialization of its candidate drugs [1]. Group 1 - Water Lily holds a total of 158 million shares, representing approximately 18.71% of the total issued shares [1]. - Water Lily has the right to receive 63.1565 million shares under the equity incentive plan, subject to the relevant conditions of those restricted share units [1]. - The board of directors believes that Water Lily's voluntary extension of the lock-up period reflects its confidence in the company's future and acknowledges the positive developments in the group's business [1].

Core Viewpoint - iFlytek Medical Technology (02506.HK) has announced a lock-up period of 12 months for shares held by pre-IPO investors, ending on December 29, 2025, indicating a commitment to stability in the company's stock performance [1] Group 1: Shareholder Information - Major shareholders include iFlytek Co., Ltd. holding 29,869,072 non-listed shares and 29,869,073 H-shares, and Anhui Kexin Venture Capital Fund holding 17,448,567 H-shares [2] - Other notable shareholders include Zhao Zhiwei, Tao Xiaodong, Lu Xiaoliang, Yin Dahai, Ji Lin, and Chen Zuji, collectively holding various amounts of non-listed shares and H-shares [2] Group 2: Lock-up Period Extension - The total shares held by the aforementioned shareholders amount to 52,758,395 H-shares, representing 68.25% of the total H-share capital, and 88,068,222 shares, accounting for 72.86% of the total share capital [3] - The extension of the lock-up period until December 29, 2026, reflects the shareholders' confidence in the company's future prospects and their intention to review the company's performance regularly [3]

Core Viewpoint - The company has received notification from cornerstone investor Yizhe Kangrui Pharmaceutical (Hong Kong) Co., Ltd. agreeing to extend the lock-up period until April 30, 2026, indicating confidence in the company's future prospects based on its technological advancements and significant clinical milestones achieved [1] Group 1 - The cornerstone investor holds a total of 9.5845 million H-shares, representing approximately 3.43% of the company's total issued H-shares [1] - The extension of the lock-up period reflects the cornerstone investor's confidence in the company's research and development capabilities [1] - The cornerstone investor will continue to review the company's performance and may consider further extending the lock-up period based on real-time developments and achieved milestones [1]

Core Viewpoint - The stock of Pagoda Biopharmaceuticals-B (02565.HK) opened over 7% higher on November 27, closing at HKD 70.00 per share, an increase of 7.03% due to the announcement of an extended lock-up period by cornerstone investor Yizhe Kangrui Pharmaceutical (Hong Kong) Co., Ltd. [2] Group 1: Lock-up Period Extension - Yizhe Kangrui has agreed not to reduce its holdings of H-shares from the original lock-up expiration date until December 31, 2025, extending the lock-up period by 35 days [3] - The extension reflects Yizhe Kangrui's confidence in Pagoda Biopharmaceuticals' technological advancements and significant progress in major clinical milestones [2][3] - Yizhe Kangrui currently holds 9.5845 million H-shares, representing approximately 3.43% of the total issued H-shares of the company [3] Group 2: Company Background and Recent Developments - Pagoda Biopharmaceuticals, established in 2008, focuses on the research and development of innovative therapies for chronic diseases, particularly in the field of metabolic disorders [5] - The company recently received approval for its first product, PB-119 (Vepidna Injection), aimed at improving blood sugar control in adults with type 2 diabetes [6] - Since its listing, Pagoda Biopharmaceuticals has seen a stock price increase of 438.46% over 129 trading days from May 27 to the present [6] Group 3: Financial Performance and Market Outlook - Pagoda Biopharmaceuticals has reported losses of CNY 279 million, CNY 283 million, and CNY 93.62 million for the years 2023, 2024, and the first half of 2025, respectively [6] - A recent report from Softbank China has given Pagoda Biopharmaceuticals a strong buy rating with a target price of HKD 101.80, citing the clinical advantages of PB-119 and potential revenue growth from 2026 to 2029 [6]

Core Viewpoint - The company has received notification from its cornerstone investor, Yizhe Kangrui Pharmaceutical (Hong Kong) Co., Ltd., agreeing to extend the lock-up period for its H shares until December 31, 2025, indicating confidence in the company's future prospects based on its technological advancements and significant clinical milestones achieved [1] Group 1 - The cornerstone investor will not reduce its holdings in any related H shares from the expiration of the original lock-up period [1] - The extension of the lock-up period reflects the cornerstone investor's confidence in the company's research and development capabilities [1] - The cornerstone investor will continue to review the company's performance and may consider further extending the lock-up period based on real-time developments and achieved milestones [1]

Core Viewpoint - The announcement highlights the extension of the lock-up period for cornerstone investor Yizhe Kangrui Pharmaceutical (Hong Kong) Co., Ltd., indicating confidence in the company's future prospects based on its technological advancements and significant clinical milestones achieved [1] Group 1: Lock-up Agreement - The company entered into a cornerstone investment agreement with Yizhe Kangrui Pharmaceutical, which includes a lock-up commitment for a total of 9,584,500 H shares for a period of 6 months from the listing date [1] - The cornerstone investor currently holds 9,584,500 H shares, representing approximately 3.43% of the company's total issued H shares [1] Group 2: Extension of Lock-up Period - The cornerstone investor has agreed not to reduce their holdings of the relevant H shares from the end of the original lock-up period until December 31, 2025 [1] - The company interprets the extension of the lock-up period as a sign of the cornerstone investor's confidence in the company's ability to advance its technological research and achieve significant clinical milestones [1] - The cornerstone investor will continue to review the company's performance and may consider further extending the lock-up period based on real-time developments and achieved milestones [1]